Pistor, Maximilian; Hoepner, Robert; Hoepner, Andreas G F; Lin, Yanan; Jung, Simon; Bassetti, Claudio L; Chan, Andrew; Salmen, Anke (2022). Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System. Therapeutic advances in neurological disorders, 15(17562864221129383), p. 17562864221129383. Sage 10.1177/17562864221129383
|
Text
17562864221129383.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (499kB) | Preview |
Background
Evidence on mortality risks associated with MS-immunotherapies during the SARS-CoV2 pandemic derived thus far mainly from single country experiences.
Objective
In this analysis, we aim to determine the frequency of COVID-19 associated fatality reports of patients receiving an MS-immunotherapy as reported to the international Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from February 2020 to March 2021.
Methods
In all, 1071 cases for this cross-sectional analysis were retrieved from FAERS and a multivariable logistic regression was performed. We adjusted for sex, age, region, month of report to FDA, immunotherapy-class and additionally for healthcare-system and pandemic-related metrics.
Result
Anti-CD20 therapies (60%) followed by sphingosine-1 phosphate modulators (12%) and dimethylfumarat (10%) were reported most frequently. In 50% of the cases, MS-phenotype is not reported, relapsing MS in 35% and progressive MS in 15%. Besides older age (odds ratio [OR]: 1.1; 95% confidence interval [CI]: 1.07-1.13; p < 0.01), anti-CD20 therapies were significantly associated with a higher risk of death (OR: 4.1; 95% CI: 1.17-14.46; p = 0.03), whereas female sex was associated with a reduced mortality risk (OR: 0.4, 95% CI: 0.22-0.72; p < 0.01).
Conclusion
Using international open access data and a multidisciplinary approach for risk prediction, we identified an increased mortality risk associated with anti-CD20 therapies, which is in line with national and multi-national cohort studies.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Pistor, Maximilian, Hoepner, Robert, Jung, Simon, Bassetti, Claudio L.A., Chan, Andrew Hao-Kuang, Salmen, Anke |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1756-2856 |
Publisher: |
Sage |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
17 Oct 2022 13:57 |
Last Modified: |
02 Mar 2023 23:36 |
Publisher DOI: |
10.1177/17562864221129383 |
PubMed ID: |
36237201 |
Uncontrolled Keywords: |
SARS-CoV2 disease-modifying therapy immunosuppression multiple sclerosis pharmacovigilance |
BORIS DOI: |
10.48350/173765 |
URI: |
https://boris.unibe.ch/id/eprint/173765 |
Actions (login required)
 |
Edit item |